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old. After adjusting for confounders, patients with COPD and
asthma were twice as likely to use FSC than those with Asthma
along (OR 1.99, 95% CI 1.73–2.29); patients with COPD alone
were 66% less likely to receive FSC than those with Asthma
along (OR 0.34, 95% CI 0.28–0.41). African-Americans were a
third less likely to be prescribed FSC than Caucasians (OR 0.69;
95% CI 0.61–0.78), and females about a third more likely than
males to use FSC (OR 1.35; 95% CI 1.16–1.57). Age was not a
signiﬁcant predictor at the 0.05 level. CONCLUSION: The
propensity to be prescribed FSC is signiﬁcantly higher in patients
with COPD/asthma than those with either disease alone. Race
and gender signiﬁcantly affect access to FSC in MMMCO, even
after adjusting for comorbidities. Cost to the patient was not a
factor, as the copayment was $1 for any prescription.
STROKE—Clinical Outcomes Studies
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LITERATURE REVIEW
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OBJECTIVES: To determine the epidemiological risk factors
associated with stroke, examine their inﬂuence on stroke-related
costs, and identify areas that need further research. METHODS:
A systematic literature search was performed (1996–2006) using
an exhaustive list of relevant search terms to identify articles
published on epidemiology of stroke and associated risk factors,
costs of stroke and economic impact of risk factors on stroke.
Studies were identiﬁed through electronic Medline® and
PubMed® searches. Manual review of bibliographies allowed
determination of additional articles. RESULTS: Out of a total of
41 included studies, 26 studies focused on stroke-associated risk
factors, while 15 studies examined the economic burden of
stroke. Apart from age and race [African-Americans have the
highest per-capita stroke costs ($25,782), followed by Hispanics
($17,201)], hypertension was the most prevalent clinical risk
factor (58.1% to 75%), followed by diabetes. Relative risk for
stroke was higher in women (increase of 2–6.5 fold) as compared
to men (1.5–2 fold) with diabetes. Renal dysfunction, pregnancy,
inﬂammation and infection, depression, chronic headache and
migraine, metabolic syndrome, cancer, and AIDS were other risk
factors identiﬁed. Total cost of stroke in United States was found
to be approximately $58 billion [2006 American Heart Associ-
ation]. Mean total cost per individual approximated $125,000.
Subarachnoid hemorrhage was reported to be the costliest stroke
sub-type. Hospitalizations and medications were the major cost
components in stroke treatment. Studies have linked few risk
factors, such as smoking and higher age, to increased stroke
treatment costs, but the impact of the majority of risk factors on
stroke costs has not been examined. CONCLUSION: Stroke has
a signiﬁcant economic impact on society, due to its morbidity
and mortality burden. However, few studies have examined the
impact of individual stroke-associated risk factors on stroke
costs. Further research demonstrating economic link of common
risk factors with stroke is warranted.
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OBJECTIVES: Subarachnoid hemorrhage (SAH) is a rare but
catastrophic event, occurring in ∼10/100,000 people, which may
result in permanent brain damage or death. Although treatment
protocols for surgical or endovascular management of SAH have
been published, widespread differences exist in patient manage-
ment. METHODS: The MedStat Marketscan databases were
used for 2000–2004 to study medical utilization for non-
traumatic SAH. Data included commercially insured and
Medicare-eligible claimants. Hospitalization records were exam-
ined for patients ages 18 and older who had a primary diagno-
sis of SAH (ICD-9 430) without any indication of trauma (n =
3241). If a hospital stay was followed by another hospitalization
which started on the date of discharge, the two were treated as
a single episode of care. Rates of surgical clipping and/or
endovascular coiling (“treatment” to secure the aneurysm), inpa-
tient death rates, day of any surgical treatment, length of stay,
and hospital readmissions were examined. RESULTS: Seventy
percent of admissions for SAH were ages <65, and 35% were
treated. Among those over age 65, only 13% were treated. 14%
of SAH patients died during the initial hospitalization. Mortal-
ity rates were lower for those treated at all ages. Among sur-
vivors treated, 45% were treated on the day of admission, and
about one-third were treated the day after admission. Among
survivors, the median length of stay was 6 days for those without
treatment, and nearly twice as long for patients who were
clipped, coiled or both. 5% of patients were readmitted to hos-
pital, with a median of 17 days between ﬁrst and second admis-
sions. CONCLUSION: Most patients presenting at the hospital
with non-traumatic SAH received no surgical or endovascular
treatment. The 35% treatment rate for SAH. is considerably
lower than in other countries, raising the possibility that patient
treatment may not be optimal in the U.S.
STROKE—Cost Studies
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OBJECTIVES: Despite solid evidence, measures for prevention,
treatment and other health practices that could reduce mortal-
ity, disability and costs are not being used routinely in Canada.
An economic model was developed to formally assess the poten-
tial clinical and economic impact of implementing a com-
prehensive stroke program. METHODS: A discrete event
simulation was designed to assess the implications of various
stroke strategies deﬁned in terms of the usage of organized stroke
units and clot-busting therapies, access to rehabilitation, stroke
awareness and prevention campaigns. Stroke incidence, modiﬁed
by whatever prevention practices are analyzed, is applied to the
Canadian population to create the simulated patients with
stroke. Each patient’s management is simulated according to his
characteristics and the interventions available given the strategy
under consideration. Over time, patients are exposed to risks of:
death, new stroke, change in functional level, and transfer to
another location of care. Each event is processed in terms of its
clinical consequences, resource use and cost. Data were obtained
from the Registry of the Canadian Stroke Network, the Cana-
dian Heart Health Survey, Statistics Canada and the Institute for
Clinical and Evaluative Sciences. RESULTS: Implementation of
widespread prevention and awareness campaigns would result in
∼127,000 fewer initial strokes over 20 years. Access to organized
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stroke care would prevent stroke-related death in 25,000
patients, serious disability in 71,000, and nursing home admis-
sion in 25,000. Despite the costs associated with such a program,
the net savings in health care costs over a 20-year period would
amount to Can$12 billion. CONCLUSION: Implementing
proven stroke therapies and practices across Canada will result
in signiﬁcant improvements in both lives and health care costs.
Analyses based on this model will support national and provin-
cial stroke strategies appropriate to their needs and resources.
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OBJECTIVES: To estimate cost-effectiveness of rFVIIa com-
pared to standard care in treating ICH over an average MCO
enrollment period of two years from a third-party payer per-
spective. METHODS: A decision-analytic model estimating cost-
effectiveness of rFVIIa 80 mcg/kg compared to standard care in
treating ICH was adapted to measure cost-effectiveness over a
time horizon (enrollment period) of two years. Input parameters
were obtained from clinical trial, claims data, and published lit-
erature. Cost of rFVIIa was based on wholesale acquisition cost.
Costs were in 2006 US dollars. Outcomes included life-years and
quality-adjusted life years (QALY). In addition, population char-
acteristics were considered, including age (over/under 65) and
gender comparisons. One-way and multivariable sensitivity
analyses were conducted to assess robustness. RESULTS: Assum-
ing a cost-effectiveness threshold of $50,000 QALY, the incre-
mental cost-effectiveness ratio (ICER) showed rFVIIa to be
cost-effective compared to standard care alone ($2924/QALY
gained). Use of rFVIIa was found to be cost-effective in both the
under- and over-65 populations ($532/QALY gained and
$5323/QALY gained, respectively). Results did not differ sub-
stantially across gender. Results were robust to changes in model
parameters. CONCLUSION: Treating ICH with rFVIIa 80 mcg/
kg within an MCO is cost-effective over the average patient
enrollment period of two years compared to standard care. Due
to potential improvements in long-term clinical outcome, treat-
ment with rFVIIa may have an even greater positive impact in
health plans with a younger population.
STROKE—Methods & Concepts
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OBJECTIVES: Health policy decision makers prefer to make
decisions with accurate estimates of the burden of the target
problem and the likely outcome of various policy options. Cre-
ating these estimates involves collecting, synthesizing, and com-
municating complex data. Simulation models provide a useful
approach for integrating complex data for producing compelling
reports. This project utilized a simulation model in the produc-
tion of a legislative document reporting on the impact of
improved stroke services in Mississippi (MS). METHODS: The
research team met with various stakeholders in stroke care
within MS, to identify a target policy issue for the legislative
report. Based on interests of MS stroke researchers, advocates,
clinicians, and policy experts, we identiﬁed the following issue:
improvements in stroke care through the use of an existing
telemedicine infrastructure as a target issue, with attention to
impact on Medicaid costs. We modiﬁed the Duke Stroke Policy
Model (DSPM), a Markov model of stroke development and
outcome to incorporate MS risk factors (from the REGARDS
survey), costs (from Medicare), and current stroke services (from
the MS Stroke Report 2005). Estimates of health and economic
impacts aimed at improving stroke care were incorporated into
an illustrative legislative report. RESULTS: The DSPM-based
report was generated as above. The illustrative report has been
reviewed by stakeholders in state policy for comment. The report
is perceived as easy-to-read and informative. CONCLUSION:
Bridging the gap between evidence and policy making will
require innovative and efﬁcient approaches to linking existing
data to produce compelling reports. This application of the
DSPM provides “proof of concept” of one approach based on
the use of a general purpose simulation model of stroke. We
believe that this is a promising strategy and will work to expand




GENERIC AND DISEASE-SPECIFIC HEALTH RELATED
QUALITY OF LIFE (HRQOL) IN STROKE SURVIVORS
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OBJECTIVES: To measure and compare generic and disease-
speciﬁc HRQoL in stroke survivors one to two years post hos-
pital discharge. METHODS: The SF-36 and the Stroke Impact
Scale (SIS) were administered to 33 stroke survivors. The stan-
dard gamble method was used to elicit utilities regarding stroke
health states. RESULTS: Of the 33 patients, 79% were male,
67% had mild stroke, 24% had moderate stroke, and 9% had
severe stroke; mean age was 66.9. Study participants scored sig-
niﬁcantly lower (p < 0.05) than the general population on seven
of the eight multi-item scales of the SF-36: Physical Functioning,
Role-Physical, General Health, Vitality, Social Functioning,
Role-Emotional, and Mental Health. Participants scored signiﬁ-
cantly lower (p < 0.001) than the general population on both
physical and mental health component summary measures.
Using the SIS, participants had a mean score of 57.23 on the
physical summary score. On the four component scales of the
physical summary score, participants had mean scores of: 44.14
on Strength, 50.31 on Hand Strength, 65.93 on Mobility, and
71.26 on Activities of Daily Living (ADL). Participants had mean
scores of 79.55 on Memory, 85.91 on Communication, 73.18
on Emotional, and 57.68 on Social Participation. SIS Physical
was signiﬁcantly correlated (p < 0.05) with both SF-36 physical
measures. Both the SF-36 mental component scores and Mental
Health domain measure were signiﬁcantly correlated with the SIS
measures of ADL, Memory, Communication, Emotional, and
Social Participation (p < 0.05). The mean standard gamble utility
score for all participants was 83.2. CONCLUSION: Stroke sur-
vivors one to two years post stroke had signiﬁcantly lower scores
than the general population on most of the SF-36 health domains
with the exception of bodily pain. Positive correlations with
major domains of the disease-speciﬁc SIS indicate that the SF-36
was sensitive to stroke health states. Further research with 
